Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other Non-Current Assets (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Other Non-Current Assets data on record, last reported at $2.8 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 9.62% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $2.8 million, down 9.62%, while the annual FY2025 figure was $2.8 million, 9.62% down from the prior year.
  • Other Non-Current Assets reached $2.8 million in Q4 2025 per ACRS's latest filing, down from $2.8 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $4.2 million in Q4 2023 and bottomed at $2.7 million in Q3 2023.
  • Average Other Non-Current Assets over 5 years is $3.3 million, with a median of $3.2 million recorded in 2024.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 113.35% in 2021, then fell 26.26% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $3.6 million in 2021, then decreased by 23.13% to $2.7 million in 2022, then soared by 52.2% to $4.2 million in 2023, then dropped by 26.26% to $3.1 million in 2024, then decreased by 9.62% to $2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $2.8 million in Q4 2025, $2.8 million in Q3 2025, and $3.0 million in Q2 2025.